Hep C Discussion Forum

Monday, February 23, 2015 - 

AbbVie today announced that results from part one of the Phase 2 portion of its Phase2/3 open-label study, TURQUOISE-I, in genotype 1 chronic HCV patients with HIV-1 co-infection were published online in The Journal of the American Medical Association (JAMA).

Additional sub-analyses also will be presented in both oral and poster presentations on Feb. 26, at the Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Wash.

As originally presented at The Liver Meeting 2014, the TURQUOISE-I study showed patients co-infected with genotype 1 hepatitis C virus and HIV-1 receiving VIEKIRA PAK and ribavirin for 12 weeks or 24 weeks achieved sustained virologic response rates 12 weeks post-treatment of 94 percent (n=29/31) and 91 percent (n=29/32), respectively.

The SVR12 rates were 91 percent (n=51/56) for subjects with HCV GT1a infection and 100 percent (n=7/7) for those with HCV GT1b infection.

"It is common for people to live with both GT1 chronic HCV and HIV, but data supporting treatment of chronic HCV in these co-infected patients have been limited," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "TURQUOISE-I is one of the few dedicated studies looking specifically at this historically difficult-to-treat population and we are proud to offer the HCV community an important new treatment option."

Link to full press release..

http://www.prnewswire.com/news-releases/results-from-abbvies-study-of-viekira-pak-ombitasvir-paritaprevir-ritonavir-tablets-dasabuvir-tablets-in-chronic-hepatitis-c-patients-with-hiv-1-co-infection-turquoise-i-published-online-in-jama-sub-analyses-to-be-presen-300039470.html